Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

By S. Dearden, J. Stevens, Yi-long Wu, D. Blowers. Annals of Oncology, 2013

629 citations recorded by the source corpus.

Background Meta-analyses were conducted to characterize patterns of mutation incidence in non small-cell lung cancer (NSCLC). Design Nine genes with the most complete published mutation coincidence data were evaluated. One meta-analysis generated a ‘mutMap’ to visually represent mutation coincidence by ethnicity (Western/Asian) and histology (adenocarcinoma [ADC] or squamous cell carcinoma). Another meta-analysis evaluated incidence of individual mutations. Extended analyses explored incidence of EGFR and KRAS mutations by ethnicity, histology, and smoking status. Results Genes evaluated were TP53, EGFR, KRAS, LKB1, EML4-ALK, PTEN, BRAF, PIK3CA, and ErbB2. The mutMap highlighted mutation coincidences occurring in ≥5% of patients, including TP53 with KRAS or EGFR mutations in patients with ADC, and TP53 with LKB1 mutation in Western patients. TP53 was the most frequently mutated gene overall. Frequencies of TP53, EGFR, KRAS, LKB1, PTEN, and BRAF mutations were influenced by histology and/or ethnicity. Although EGFR mutations were most frequent in patients with ADC and never/light smokers from Asia, and KRAS mutations were most frequent in patients with ADC and ever/heavy smokers from Western countries, both were detected outside these subgroups. Conclusions Potential molecular pathology segments of NSCLC were identified. Further studies of mutations in NSCLC are warranted to facilitate more specific diagnoses and guide treatment.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/79d54d582f4a0275c48101e0f91a5681f41b83ed

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. B. Chan
2. B. Hughes

Citations in the corpus

• Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation (2015, background): “9% of Asian NSCLC patients harbor EGFR mutation.(3) Two major types of EGFR kinase mutations include exon-19 deletions and L858R mutation in exon 21,(4,5) which confer sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib.”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “These mutations in receptors or protein kinases can stimulate a complex cascade of cross signalling pathways such as the RAS-RAF-MEK-ERK or MAPK, PI3K-AKTmTOR or JAK-STAT pathways (Figure 2) (3,4,7,18,20).”
• EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). (2015, background): “Results of the first mutMap study similarly indicated that although EGFR mutations occurred more frequently in females, Asians, and never-/light-smokers, mutations were also found outside of these three subgroups [5].”